循环肿瘤细胞（CTCs）用于非小细胞肺癌（NSCLC）治疗的无创监测和个体化治疗。
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.
作者信息
Pawlikowska Patrycja, Faugeroux Vincent, Oulhen Marianne, Aberlenc Agathe, Tayoun Tala, Pailler Emma, Farace Françoise
机构信息
INSERM, U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment", Villejuif, France.
Gustave Roussy, Université Paris-Saclay, "Circulating Tumor Cells" Translational Platform, Villejuif, France.
出版信息
J Thorac Dis. 2019 Jan;11(Suppl 1):S45-S56. doi: 10.21037/jtd.2018.12.80.
Abstract
Growing evidences for tumor heterogeneity confirm that single-tumor biopsies frequently fail to reveal the widespread mutagenic profile of tumor. Repeated biopsies are in most cases unfeasible, especially in advanced cancers. We describe here how circulating tumor cells (CTCs) isolated from minimally invasive blood sample might inform us about intratumor heterogeneity, tumor evolution and treatment resistance. We also discuss the advances of CTCs research, most notably in molecularly selected non-small cell lung cancer (NSCLC) patients, highlighting challenges and opportunities related to personalized therapy.
摘要
越来越多关于肿瘤异质性的证据证实，单次肿瘤活检常常无法揭示肿瘤广泛的诱变特征。在大多数情况下，重复活检并不可行，尤其是在晚期癌症中。我们在此描述了如何从微创血样中分离出的循环肿瘤细胞（CTC）能够让我们了解肿瘤内异质性、肿瘤演变和治疗耐药性。我们还讨论了CTC研究的进展，最显著的是在分子选择的非小细胞肺癌（NSCLC）患者中的进展，强调了与个性化治疗相关的挑战和机遇。
相似文献
1
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies.
J Thorac Dis. 2019 Jan;11(Suppl 1):S45-S56. doi: 10.21037/jtd.2018.12.80.
2
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in -Rearranged Non-Small-Cell Lung Cancer.
Clin Cancer Res. 2019 Nov 15;25(22):6671-6682. doi: 10.1158/1078-0432.CCR-19-1176. Epub 2019 Aug 22.
3
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Lung Cancer. 2018 Jun;120:108-112. doi: 10.1016/j.lungcan.2018.04.001. Epub 2018 Apr 3.
4
Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells.
Adv Exp Med Biol. 2017;994:255-273. doi: 10.1007/978-3-319-55947-6_14.
5
Circulating tumor cells and CDX models as a tool for preclinical drug development.
Transl Lung Cancer Res. 2017 Aug;6(4):397-408. doi: 10.21037/tlcr.2017.08.01.
6
Progress and application of circulating tumor cells in non-small cell lung cancer.
Mol Ther Oncolytics. 2021 May 19;22:72-84. doi: 10.1016/j.omto.2021.05.005. eCollection 2021 Sep 24.
7
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
Micromachines (Basel). 2018 Feb 28;9(3):100. doi: 10.3390/mi9030100.
8
Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
Oncotarget. 2016 Apr 26;7(17):23251-62. doi: 10.18632/oncotarget.8136.
9
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Ann Oncol. 2015 Jul;26(7):1408-15. doi: 10.1093/annonc/mdv165. Epub 2015 Apr 6.
10
Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
J Cancer Res Clin Oncol. 2020 Oct;146(10):2621-2630. doi: 10.1007/s00432-020-03244-4. Epub 2020 Jul 13.
引用本文的文献
1
Evaluating circulating tumour cell enrichment techniques to establish an appropriate method for clinical application in glioblastomas.
Front Neurol. 2024 Feb 28;15:1358531. doi: 10.3389/fneur.2024.1358531. eCollection 2024.
2
Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.
Int J Mol Sci. 2023 Nov 8;24(22):16085. doi: 10.3390/ijms242216085.
3
High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells.
Nat Commun. 2022 Jun 13;13(1):3385. doi: 10.1038/s41467-022-31009-9.
4
Identification of plasma exosomes long non-coding RNA HAGLR and circulating tumor cells as potential prognosis biomarkers in non-small cell lung cancer.
Transl Cancer Res. 2019 Oct;8(6):2264-2273. doi: 10.21037/tcr.2019.09.43.
5
Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas?
J Appl Biomed. 2021 Dec;19(4):181-189. doi: 10.32725/jab.2021.019. Epub 2021 Sep 16.
6
Progress and application of circulating tumor cells in non-small cell lung cancer.
Mol Ther Oncolytics. 2021 May 19;22:72-84. doi: 10.1016/j.omto.2021.05.005. eCollection 2021 Sep 24.
7
Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Cancers (Basel). 2021 Aug 25;13(17):4280. doi: 10.3390/cancers13174280.
8
Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery.
BMJ Open Respir Res. 2021 Sep;8(1). doi: 10.1136/bmjresp-2021-000917.
9
Evaluation of Monocarboxylate Transporter 4 ( Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.
Front Cell Dev Biol. 2021 Apr 22;9:641978. doi: 10.3389/fcell.2021.641978. eCollection 2021.
10
Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.
Sci Rep. 2021 Jan 27;11(1):2313. doi: 10.1038/s41598-021-82068-9.
本文引用的文献
1
Chromosomal instability drives metastasis through a cytosolic DNA response.
Nature. 2018 Jan 25;553(7689):467-472. doi: 10.1038/nature25432. Epub 2018 Jan 17.
2
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
3
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
4
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients.
Oncotarget. 2017 Jul 31;8(35):59408-59416. doi: 10.18632/oncotarget.19722. eCollection 2017 Aug 29.
5
Molecular analysis of single circulating tumour cells following long-term storage of clinical samples.
Mol Oncol. 2017 Dec;11(12):1687-1697. doi: 10.1002/1878-0261.12113. Epub 2017 Oct 24.
6
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
Ann Oncol. 2017 Jul 1;28(7):1523-1531. doi: 10.1093/annonc/mdx156.
7
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
8
Succinct workflows for circulating tumor cells after enrichment: From systematic counting to mutational profiling.
PLoS One. 2017 May 8;12(5):e0177276. doi: 10.1371/journal.pone.0177276. eCollection 2017.
9
Circulating Tumor Cells with Aberrant Copy Number Predict Progression-Free Survival during Crizotinib Treatment in -Rearranged Non-Small Cell Lung Cancer Patients.
Cancer Res. 2017 May 1;77(9):2222-2230. doi: 10.1158/0008-5472.CAN-16-3072.
10
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364.
Zotero 插件